Sugi Predict

Sugi Predict / Compounds / SCHEMBL18448447

SCHEMBL18448447

SCHEMBL18448447

Cn1cc(-c2cnc3[nH]nc(-c4cc5cccnc5[nH]4)c3c2)cn1

nearest known ligand 0.70

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CLK2 P49760 11/20 0.70
▸ DYRK1A Q13627 11/20 0.70
▸ CLK3 P49761 10/20 0.51
▸ MAPT P10636 1/20 0.47
▸ WNT1 P04628 1/20 0.47
▸ AXL P30530 2/20 0.44
▸ PIM1 P11309 4/20 0.43
▸ PIM3 Q86V86 1/20 0.43
▸ PIM2 Q9P1W9 1/20 0.43
▸ RIPK1 Q13546 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18441530 0.88 CLK2 (0.64) CLK2DYRK1ACLK3WNT1AXL
SCHEMBL18453187 0.86 CLK2 (0.52) CLK2DYRK1ACLK3AXLPIM1
SCHEMBL18437376 0.84 CLK2 (0.51) CLK2DYRK1ACLK3MAPTAXL
SCHEMBL18452074 0.84 CLK2 (0.52) CLK2DYRK1ACLK3MAPTAXL
SCHEMBL18452754 0.84 CLK2 (0.51) CLK2DYRK1ACLK3MAPTWNT1
SCHEMBL18448558 0.82 CLK2 (0.61) CLK2DYRK1ACLK3WNT1
SCHEMBL17564774 0.82 CLK2 (0.53) CLK2DYRK1ACLK3MAPTWNT1
SCHEMBL18440826 0.82 CLK2 (0.70) CLK2DYRK1ACLK3MAPTWNT1
SCHEMBL18447513 0.82 DYRK1A (0.67) CLK2DYRK1ACLK3WNT1
SCHEMBL18448187 0.82 CLK2 (0.59) CLK2DYRK1ACLK3WNT1RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10285983-B2 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-14 — — US claimed
WO-2017023996-A1 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC. (US) 2017-02-09 — — WO claimed
US-20230000842-A1 METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2023-01-05 — — US disclosed
WO-2020150552-A2 METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK SAMUMED, LLC (US) 2020-07-23 — — WO disclosed
US-10285983-B2 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-14 — — US disclosed
US-10285983-B2 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10285983-B2 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof WNT1, WNT3A, WNT3 CLK2 2043/4885DYRK1A 849/4885CLK3 2290/4885
US-20230000842-A1 METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK CLK2, CLK3, CLK1 CLK2 1/4885DYRK1A 7/4885CLK3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.